Bone density and remodeling after discontinuation of sequential therapy for premenopausal idiopathic osteoporosis
Abstract
In premenopausal IOP, BMD gains on teriparatide-denosumab were maintained on bisphosphonate over 1 year. In 19 followed after bisphosphonate, there was a significant bone loss over 6M, leading to retreatment in some. BMD remained significantly above pretreatment baseline. In premenopausal IOP, the optimal duration of bisphosphonate after denosumab requires further study. We have previously reported that sequential teriparatide-denosumab resulted in large BMD increases in premenopausal women with idiopathic osteoporosis (IOP), and that BMD remained stable with bisphosphonate (alendronate or zoledronate) for 1 year after denosumab cessation (Bisphosphonate Extension Study; BES Year 1). To determine the durability of this effect, an observation year (BES Year 2) off therapy was planned.
Participants: 19 women, aged 44 ± 8, with premenopausal IOP.
Measures: BMD by DXA, serum CTX every 6 months (M).
Results: On sequential teriparatide-denosumab, BMD increased by 23 ± 9% at the spine and 12 ± 7% at the total hip. In BES Year 1 on bisphosphonate, BMD and CTX did not change significantly at 6M or 12M. From 12-18M of BES Year 2, BMD declined by 4.2 ± 2.5% at the spine and 1.4 ± 2.1% at the total hip (both p < 0.05); other sites remained stable. CTX increased by 218 ± 210 pg/ml (p < 0.05). At 18M, ten participants resumed bisphosphonates because of bone loss or low BMD and nine continued observation. By the end of BES Year 2, spine BMD stabilized in both groups. BMD at the spine and…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.